402 results about "Ulcerative colitis" patented technology

The invention belongs to the technical field of nano material synthesis, and particularly relates to baicalein-copper nano microgel as well as a preparation method and application thereof. According to the invention, copper ions and baicalein are coordinated to form nanowires, and the nanowires are coated with hyaluronic acid (HA) to prepare the nano microgel. The method is carried out at normal temperature, is simple in process and high in yield, and does not need toxic solvents; the obtained microgel has high stability (gastric acid resistance), targeted delivery (CD44 receptor mediation) and multiple biological activities (oxidation resistance and inflammation resistance). Animal experiments show that the pharmaceutical composition can significantly relieve ulcerative colitis, the dosage is as low as 5 mg / kg, the pharmaceutical composition is non-toxic, and a new strategy is provided for treatment of inflammatory diseases.

The invention relates to the technical field of biological medicine, in particular to an ulcerative colitis disease clearance evaluation molecular marker and application thereof. By detecting the expression level of the HMGCS2 gene in a sample, the ulcerative colitis disease clearance state and disease activity period can be evaluated, and the method is used for curative effect monitoring, recurrence prediction and individualized treatment strategy formulation of ulcerative colitis and has important clinical application value and market prospect.

A Bifidobacterium longum subsp. longum dipro-017. The Bifidobacterium longum subsp. longum dipro-017 used has the ability to metabolize tryptophan to produce indole-3-lactic acid, can inhibit the pathogenic bacteria Salmonella Typhimurium, Staphylococcus aureus, and Escherichia coli, and can effectively mitigate weight loss caused by ulcerative colitis, improve a DAI score, improve colon length, mitigate the content of lipopolysaccharide (LPS) in blood, and increase the level of anti-inflammatory cytokine IL-10, as well as mitigate the content of bone metabolism indicators tartrate-resistant acid phosphatase (TRAP) and N-terminal propeptide of type I procollagen (PINP) in blood.

The invention discloses application of copper-amino acid nano enzyme in preparation of anti-inflammatory drugs, and relates to the technical field of biomedical new materials, amino acids comprise glycine, arginine, histidine, threonine, phenylalanine and cysteine; the ratio of the amino acid to the copper ions is 1: (0.5-5), and the synthesis temperature of the copper-cysteine nano enzyme is 25-125 DEG C. The copper-amino acid nano-enzyme library established by the invention has efficient hydroxyl free radical, superoxide free radical and hydrogen peroxide scavenging activity; wherein the copper-cysteine nano-enzyme shows the highest enzymatic activity, and shows low toxicity and good biocompatibility in both the cell level and the animal level; meanwhile, the copper-cysteine nano-enzyme also shows anti-inflammatory activity and anti-oxidative stress activity, can remarkably improve cell inflammation and body inflammation, relieves and treats dextran sodium sulfate induced mouse ulcerative colitis, and can be further applied to preparation of drugs for treating inflammatory bowel diseases.

The invention discloses an ulcerative colitis image classification method based on a multi-scale attention fusion network, belongs to the technical field of image information mining and classification, and combines a staged feature extraction backbone network, a multi-scale attention fusion module (SCHL) and a classification module. The ulcerative colitis lesion image classification method has the advantages that significant advantages are shown in ulcerative colitis lesion image automatic classification tasks, an OfficientNet backbone network has staged feature extraction capacity, multi-level information from shallow texture to deep semantics in lesion images can be effectively captured, an SCHL module performs modeling by fusing channel attention, space attention and level high-frequency information, and the ulcerative colitis lesion image classification efficiency is improved. The model is guided to focus on a key lesion area, background interference is inhibited, feature discrimination is enhanced, the recognition ability of the model to a fine-grained lesion form and the generalization ability of the model to a complex clinical image are remarkably improved, and higher accuracy and robustness are achieved in refined classification of ulcerative colitis.

The invention discloses anti-inflammatory polypeptide nanoparticles and a preparation method thereof, and belongs to the technical field of bioactive peptides. The anti-inflammatory polypeptide nano-particles are nano-particles obtained by coating polypeptide with an anti-inflammatory effect with chitosan and sodium tripolyphosphate, the polypeptide with the anti-inflammatory effect contains bioactive peptides of which the amino acid sequences are YAADQ, FPYTT and YVTYA. The phycocyanin anti-inflammatory peptide is natural in source, the performance of the phycocyanin anti-inflammatory peptide can be remarkably improved through the nanometer embedding technology, and compared with traditional drugs, the phycocyanin anti-inflammatory peptide has lower toxic and side effects and potential cost advantages. The polypeptide nanoparticles prepared by the invention can effectively prevent the phycocyanin anti-inflammatory peptide from being degraded in the digestive tract, have a remarkable treatment effect on mice with ulcerative colitis, and have an important application prospect in preparation of ulcerative colitis prevention and treatment products.

The invention relates to the technical field of microorganisms, in particular to an anti-inflammatory compound probiotic and application thereof.Lactobacillus rhamnosus LGD-0817, lactobacillus rhamnosus LDL-1708 and lactobacillus plantarum LEP-1208 serve as basic dominant bacteria and then are compounded with multiple bacteria such as lactobacillus casei, lactobacillus delbrueckii and lactobacillus paracasei, the multiple bacteria can be matched and promoted mutually, and the anti-inflammatory compound probiotic has the anti-inflammatory effect. The traditional Chinese medicines jointly play a significant role in improving ulcerative colitis; the anti-inflammatory compound probiotics are used for traditional Chinese medicine fermentation, and the obtained traditional Chinese medicine fermentation composition can regulate intestinal flora, enhance the barrier function of the intestinal tract, inhibit release of proinflammatory factors, improve the shortening of the colon length of a mouse with colitis, inhibit the levels of proinflammatory cytokines IL-1beta, IL-6 and TNF-alpha, competitively inhibit colonization of pathogenic bacteria and improve the colonization of colitis. The method shows a good comprehensive intervention effect in a DSS-induced mouse ulcerative colitis model, and has clinical practical value.

The invention discloses an application of engineered citrobacter freundii in fermentation synthesis of a stable body. The engineered citrobacter freundii is citrobacter freundii overexpressing a polyphosphate kinase gene Ppk1. The stable body prepared by fermenting the engineered citrobacter freundii is rich in polyphosphates and polyamines, particularly, the content of the polyamines can be up to 21wt%, the polyphosphates in the stable body can store the polyamines in an ionic bond combination mode, the combined polyamines are insoluble in water, a natural anion coating is generated, and the stability of the stable body is improved. And the sustained-release tablet is not easily taken by intestinal epithelial cells, so that the sustained-release tablet has a certain sustained-release effect. The medicine prepared by taking the compound as a main active ingredient shows a remarkable curative effect in ulcerative colitis treatment, has the comprehensive effects of reducing oxidative stress, enhancing the anti-inflammatory ability of a body and regulating immunity, is suitable for patients of all ages, and has outstanding application value and market prospect.

The invention relates to a quercetin nanocrystal and a preparation method and application of a quercetin nanocrystal preparation, and the preparation method of the quercetin nanocrystal comprises the following steps: step 1, mixing a quercetin absolute ethyl alcohol solution and a geniposide aqueous solution, and centrifuging to obtain a precipitate; and 2, washing the precipitate with distilled water, discarding the supernatant, adding the precipitate into water, dispersing to obtain a quercetin-geniposide suspension, and freeze-drying to obtain the quercetin nanocrystal. The geniposide is used as a carrier to prepare the quercetin nanocrystal, the geniposide is used for regulating and controlling the morphology and size of the quercetin nanocrystal to enable the quercetin nanocrystal to play a synergistic effect, and the effect of the quercetin on treating ulcerative colitis is greatly improved.

This paper discusses a strain of Bifidobacterium animalis subsp. lactis B7 and its composition and applications, belonging to the field of microbial technology. The specific strain is Bifidobacterium animalis subsp. lactis B7. Bifidobacterium animalis subsp. lactis Bifidobacterium lactis subspecies B7 was deposited at the China Center for Type Culture Collection on April 19, 2024, with accession number CCTCC NO: M2024734. This invention also discloses the application of the B7 fermentation composition in the preparation of drugs for the prevention and treatment of ulcerative colitis, constipation, and constipation-predominant ulcerative colitis. This animal bifidobacterium lactis subspecies B7 produces high levels of short-chain fatty acids and indolepropionic acid, utilizes sulforaphane to generate sulforaphane, increases intestinal peristalsis, effectively alleviates the disease activity index (DAI) and weight loss caused by ulcerative colitis or inflammatory bowel disease, significantly reduces colonic damage in mice, protects the mucosal layer, has anti-inflammatory effects, inhibits pathogens, and improves intestinal barrier function.

Disclosed herein is a method of treating an individual afflicted with moderate to severe ulcerative colitis, the method comprising: administering a local inhibitor of interleukin-23 (IL-23) and tumor necrosis factor alpha (TNF-alpha) to an intestine of the individual.

The invention relates to a novel polypeptide and application thereof. The polypeptide provided by the invention is short in peptide chain and faster and better in absorption. Experimental results show that the polypeptide provided by the invention shows an obvious enteric cavity dilatation relieving effect in pharmacodynamic tests of a zebra fish inflammatory bowel disease model and a rat inflammatory bowel disease model. The polypeptide provided by the invention has a remarkable colitis relieving effect, and can be used for preparing a medicine for treating enteritis, especially a medicine for treating ulcerative colitis.

The invention discloses lotus leaf homogeneous polysaccharide LLP3-1 as well as a separation and purification method and application thereof, and belongs to the technical field of plant polysaccharide. The lotus leaf homogeneous polysaccharide LLP3-1 is composed of rhamnose, arabinose, galactose and galacturonic acid, the molar percentage of monosaccharide is 21.95: 25.33: 21.10: 31.62, the lotus leaf homogeneous polysaccharide LLP3-1 is acidic pectin polysaccharide with RG-I as a main structural domain and with part of side chains, the main chain is mainly composed of galacturonic acid and rhamnose, and the side chains are mainly composed of arabinose and galactose. The lotus leaf homogeneous polysaccharide LLP3-1 has the beneficial effects that the lotus leaf homogeneous polysaccharide LLP3-1 can obviously improve the symptoms of ulcerative colitis; the compound can be widely applied to preparation of medicines for treating ulcerative colitis, medicines for inhibiting proinflammatory factor secretion, antioxidation medicines, medicines for improving intestinal barrier integrity and functions, medicines for promoting short-chain fatty acid generation and medicines for improving intestinal flora disorder of ulcerative colitis.

The present invention relates to a composition for preventing or treating inflammatory diseases, comprising a Lactobacillus sakei CVL-001 strain. The composition activates NOD2, which is an inflammation regulator, and exhibits the effects of inhibiting weight loss and improving clinical activity scores (disease activity index; DAI) in an animal model in which ulcerative colitis is induced, and thus the present invention can be effectively used in the prevention, treatment or alleviation of inflammatory diseases.

Provided is recombinant protein for ulcerative colitis treatment or prevention that is recombinant protein based on milk fat globule-EGF factor 8 (MFG-E8) protein, consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, to be administered to a target for treatment or prevention, thereby expecting treatment or prevention of ulcerative colitis. Further, provided is a composition for ulcerative colitis treatment or prevention containing recombinant protein based on milk fat globule-EGF factor 8 (MFG-E8) protein, consisting of an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 3, as an active ingredient.

Novel compounds that act as inhibitors of alpha4beta7 integrin are disclosed. Pharmaceutical compositions and methods of use of inhibitors of [alpha] 4 [beta] 7 integrin are disclosed. In particular, methods of using the [alpha] 4 [beta] 7 inhibitors in the treatment of diseases or conditions associated with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease.

The invention discloses a preparation method and application of ulcerative colitis resisting kelp fucoidin, and belongs to the technical field of polysaccharide preparation and application, the preparation method is used for preparing the kelp fucoidin, and the preparation method comprises the following steps: taking kelp as a raw material, cleaning, drying, crushing and sieving, and then performing reflux degreasing to obtain kelp powder; carrying out hot water-ultrasonic synergistic extraction on the algae powder, and carrying out centrifugation and rotary evaporation concentration to obtain a supernatant; performing graded alcoholization and deproteinization treatment on the supernate to obtain a deproteinized polysaccharide solution; and dialyzing the deproteinized polysaccharide solution to remove impurities, freeze-drying to obtain the kelp fucoidin, and applying the obtained kelp fucoidin to treatment of ulcerative colitis. The preparation process is simple, efficient and high in repeatability, compared with an artificially synthesized ulcerative colitis resisting medicine mesalazine, the obtained natural fucoidin has the same level of ulcerative colitis resisting activity, a new natural active raw material is provided for ulcerative colitis treatment, and the natural fucoidin has a good application prospect.

The invention relates to the field of polypeptides, in particular to an Antarctic krill active peptide and a preparation method and application thereof. The sequence of the euphausia superba active peptide comprises at least one of LFP, FDL and FSL. The Antarctic krill active peptide has a good anti-inflammatory effect and can be used for preparing the Antarctic krill selenium chelating peptide, and the prepared Antarctic krill selenium chelating peptide has a good effect in the aspect of treating ulcerative colitis.

The present invention provides the use of an aerolysin inhibitor in the preparation of a medicament for preventing or treating ulcerative colitis in a subject. The present invention also provides a method and composition for preventing or treating ulcerative colitis.

Disclosed herein is a method for treating, preventing, and / or slowing the progression of various chronic inflammatory condition groups including: (1) the Type 2 Diabetes group (Metabolic Syndrome (MET), obesity, hyperglycemia); (2) ARDS (Acute Respiratory Distress Syndrome); (3) chronic autoimmune inflammatory conditions (Rheumatoid Arthritis (RA), Lupus, and Psoriasis); (4) inflammatory bowel diseases (IBD), such as Crohn's disease and ulcerative colitis; (5) metabolite group-mediated diseases (atherosclerosis, hypertension, and congestive heart failure); and (6) eating disorders, such as Prader-Willi Syndrome and other monogenic and symptomatic obesity disorders including leptin pathway defects, each method comprising orally administering a pharmaceutical composition comprising a denatonium salt. The present disclosure is based on the results of a series of studies that tracked biomarker cluster levels to track mediators of inflammatory conditions and mediators of gut signaling hormones in response to orally administered denatonium salts.

The invention provides a red ginseng fruit exosome, which is prepared by taking fresh fruits of Campumoea lancifolia (Roxb.) Merr. As raw materials, and extracting the red ginseng fruit exosome by adopting a differential centrifugation method and an ultra-high-speed centrifugation method. The invention also provides a preparation method and application of the exosome. The crataegus pinnatifida fruit exosome has the functions of resisting inflammation, regulating immunity and the like, and can inhibit colitis, improve the intestinal environment and inhibit expression of cell inflammatory factors, so that the effect of relieving ulcerative colitis symptoms is achieved, and a theoretical basis and a scientific basis are provided for treating ulcerative colitis by using the crataegus pinnatifida fruit-sourced exosome.

The present invention relates to compounds that are peptide inhibitors of the interleukin-23 receptor (IL-23R) and to their use in the treatment or prevention of a variety of diseases, conditions or disorders, including inflammatory diseases, such as inflammatory bowel disease (e.g. Crohn's disease or ulcerative colitis), psoriasis and psoriatic arthritis. The compound has good physical and chemical stability in the gastrointestinal tract.

IL-23 binding proteins (e.g., antibodies) and methods of use, including methods of treating inflammatory bowel disease (e.g., ulcerative colitis or Crohn's disease) comprising administering IL-23 binding proteins.

The application belongs to the technical field of biological medicine, and particularly discloses application of Lactobacillus delbrueckii surface protein DUF4430 in preparation of a medicine for improving symptoms of ulcerative colitis, and preventing and / or treating ulcerative colitis. The application provides a new use of the Lactobacillus delbrueckii surface protein DUF4430, including application in preparation of a medicine for improving symptoms of ulcerative colitis, and preventing and / or treating ulcerative colitis. Animal experiments show that the Lactobacillus delbrueckii surface protein DUF4430 can relieve DSS-induced ulcerative colitis in mice, improve weight loss, shorten colon length, and reduce colon mucosal injury, reduce the content of pro-inflammatory cytokines (such as IL-1β and IL-6) in the colon, increase the content of anti-inflammatory cytokines (such as IL-10), reduce the proportion of pro-inflammatory macrophages in the spleen and colon, and inhibit the pro-inflammatory phenotype of macrophages, and therefore can be used for preparing a medicine for improving symptoms of ulcerative colitis, and preventing and treating ulcerative colitis.

The invention belongs to the technical field of traditional Chinese medicines, and provides a traditional Chinese medicine compound composition for treating ulcerative colitis and a preparation method thereof. Chinese pulsatilla root and coptis chinensis are used for clearing away heat and toxic materials, cooling blood and stopping dysentery; bletilla striata has the effects of astringing to stop bleeding, diminishing swelling and promoting granulation, fried sanguisorba officinalis has the effects of cooling blood, stopping bleeding, detoxifying and astringing sores, golden cypress has the effects of clearing heat and drying dampness, and ash bark has the effects of inducing astringency and stopping dysentery, all serve as ministerial drugs, assist the monarch drugs to play roles, enhance the curative effects of the monarch drugs and assist the monarch drugs in purging fire and detoxifying. The fried radix paeoniae alba is used for regulating menstruation and relieving pain, the root of Chinese toona astringents and stopping bleeding, and the radix scutellariae is used for clearing away heat and toxic materials, which are all adjuvant drugs. The liquorice serves as a conductant drug and can relieve spasm and pain and resolve the drugs. All the traditional Chinese medicine components are in synergistic interaction, so that the traditional Chinese medicine compound composition has the effects of clearing away heat and toxic materials, astringing intestines and stopping bleeding, and astringing sores and promoting tissue regeneration, and can be used for treating ulcerative colitis.

The present invention is directed to the use of antiviral agents, in particular valomaciclovir stearate and its polymorph Form A, as well as H2G (omaciclovir) to treat multiple sclerosis in combination with other agents, as well as the use of these agents to treat diseases and conditions such as chronic mononucleosis, long COVID, chronic fatigue syndrome, fibromyalgia, Crohn's disease, ulcerative colitis, rheumatoid arthritis, systemic lupus erythematosus, Graves' disease, Alzheimer's disease, mesial temporal lobe seizures, Epstein-Barr-virus-linked autism, or an Epstein-Barr-virus-linked cancer.

The present application relates to the field of traditional Chinese medicine, and specifically relates to the use of a Chinese herbal medicine combination in the preparation of a medicament for the treatment of inflammatory bowel disease, in particular ulcerative colitis, a method of preparing a medicament comprising the Chinese herbal medicine combination, and a method of treating an individual having inflammatory bowel disease, in particular ulcerative colitis.

The application discloses sodium alginate-kelp polysaccharide-ganoderic acid D nanoparticles for targeted treatment of ulcerative colitis and a preparation method and application thereof. Raw materials of the nanoparticles include sodium alginate, kelp polysaccharide and ganoderic acid D with a mass ratio of 20-30:2-5:8-12. The sodium alginate-kelp polysaccharide-ganoderic acid D nanoparticles are prepared by taking sodium alginate gel as a carrier and loading kelp polysaccharide and ganoderic acid D in the carrier, and the nanoparticles are used for preventing and / or relieving ulcerative colitis, can have antioxidant effect, target regulation of intestinal barrier function, reduction of inflammatory reaction and improvement of intestinal health, and provide a new method for ulcerative colitis.

The invention discloses a copper ion-kaempferol nano-composite and application thereof in treatment of inflammatory bowel disease, the obtained nano-composite has very strong stability and active oxygen scavenging ability, and has excellent oxidation resistance and anti-inflammatory ability, and the specific performance is as follows: the surface is negatively charged, and the nano-composite can specifically target the diseased region of intestinal inflammation, so that the copper ion-kaempferol nano-composite can be applied to treatment of inflammatory bowel disease. The intestinal mucosal barrier injury is effectively repaired, the imbalance state of intestinal flora is adjusted, and the intestinal inflammation microenvironment is remarkably improved; the antioxidant and anti-inflammatory capacities of cells can be enhanced by regulating and controlling a PI3K-Akt signal channel and a nuclear factor kappa B (NF-kappa B) signal channel; the compound shows an excellent treatment effect in mouse models of typical inflammatory bowel diseases such as ulcerative colitis and Crohn's disease and related complications of bowel diseases. The invention provides a new way for constructing a multi-target and multi-layer treatment platform for the inflammatory bowel disease of a natural product.